• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Clinical trials update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, PROSPECT and statins for heart failure.

作者信息

Cleland John G F, Abdellah Ahmed Tageldien, Khaleva Olga, Coletta Alison P, Clark Andrew L

机构信息

Department of Cardiology, University of Hull, Castle Hill Hospital, Cottingham, Kingston-upon-Hull, HU16 5JQ, UK.

出版信息

Eur J Heart Fail. 2007 Oct;9(10):1070-3. doi: 10.1016/j.ejheart.2007.09.005. Epub 2007 Sep 24.

DOI:10.1016/j.ejheart.2007.09.005
PMID:17890152
Abstract

This article provides information and a commentary on trials relevant to the pathophysiology, prevention and treatment of heart failure, presented at the European Society of Cardiology Congress 2007. Unpublished reports should be considered as preliminary data, as analyses may change in the final publication. In the 3CPO study, non-invasive ventilation produced a more rapid resolution of symptoms in patients hospitalised with acute cardiogenic pulmonary oedema; but had no effect on survival, compared to standard oxygen therapy. The ALOFT study showed that the selective oral renin inhibitor aliskiren reduces plasma BNP levels and is well tolerated in patients with heart failure receiving ACE inhibitors or ARBs, although the study was not powered to show clinical benefit. In the PROSPECT study, no echocardiographic measure of mechanical dyssynchrony was identified that was useful for identifying patients more or less likely to respond to CRT. Low dose atorvastatin reduced the incidence of sudden cardiac death in a small placebo controlled study of patients with advanced chronic heart failure.

摘要

相似文献

1
Clinical trials update from the European Society of Cardiology Congress 2007: 3CPO, ALOFT, PROSPECT and statins for heart failure.
Eur J Heart Fail. 2007 Oct;9(10):1070-3. doi: 10.1016/j.ejheart.2007.09.005. Epub 2007 Sep 24.
2
Clinical trials update from the European Society of Cardiology heart failure meeting: TNT subgroup analysis, darbepoetin alfa, FERRIC-HF and KW-3902.欧洲心脏病学会心力衰竭会议临床试验最新消息:TNT亚组分析、阿法达贝泊汀、FERRIC-HF和KW-3902
Eur J Heart Fail. 2006 Aug;8(5):547-9. doi: 10.1016/j.ejheart.2006.07.003. Epub 2006 Aug 1.
3
Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.2007年维也纳欧洲心脏病学会大会临床试验最新进展:PROSPECT、EVEREST、ARISE、ALOFT、FINESSE、布拉格-8、心肌梗死的CARESS及急性冠状动脉综合征患者经皮冠状动脉介入治疗随机评估试验(ACUITY)
Cardiovasc Drugs Ther. 2007 Dec;21(6):459-65. doi: 10.1007/s10557-007-6069-4.
4
Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial.阿利吉仑在背景剂量 ACE 抑制剂的心力衰竭患者中的效果:ALOFT 试验的回顾性分析。
Cardiovasc Drugs Ther. 2011 Aug;25(4):315-21. doi: 10.1007/s10557-011-6319-3.
5
Statins and autonomic function in chronic heart failure.慢性心力衰竭中的他汀类药物与自主神经功能
Cardiovasc Drugs Ther. 2005 May;19(3):167-8. doi: 10.1007/s10557-005-2766-z.
6
[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].
Med Klin (Munich). 2003 Jun 15;98(6):326-34. doi: 10.1007/s00063-003-1266-9.
7
Clinical Trial Updates and Hotline Sessions presented at the European Society of Cardiology Congress 2007: (FINESSE, CARESS, OASIS 5, PRAGUE-8, OPTIMIST, GRACE, STEEPLE, SCAAR, STRATEGY, DANAMI-2, ExTRACT-TIMI-25, ISAR-REACT 2, ACUITY, ALOFT, 3CPO, PROSPECT, EVEREST, COACH, BENEFiT, MERLIN-TIMI 36, SEARCH-MI, ADVANCE, WENBIT, EUROASPIRE I-III, ARISE, getABI, RIO).在2007年欧洲心脏病学会大会上展示的临床试验更新及热线会议:(FINESSE、CARESS、OASIS 5、PRAGUE - 8、OPTIMIST、GRACE、STEEPLE、SCAAR、STRATEGY、DANAMI - 2、ExTRACT - TIMI - 25、ISAR - REACT 2、ACUITY、ALOFT、3CPO、PROSPECT、EVEREST、COACH、BENEFiT、MERLIN - TIMI 36、SEARCH - MI、ADVANCE、WENBIT、EUROASPIRE I - III、ARISE、getABI、RIO)
Clin Res Cardiol. 2007 Nov;96(11):767-86. doi: 10.1007/s00392-0591-z. Epub 2007 Oct 25.
8
Clinical trials update from European Society of Cardiology meeting 2008: TIME-CHF, BACH, BEAUTIFUL, GISSI-HF, and HOME-HF.2008年欧洲心脏病学会会议临床试验最新进展:TIME-CHF、BACH、BEAUTIFUL、GISSI-HF及HOME-HF
Eur J Heart Fail. 2008 Dec;10(12):1264-7. doi: 10.1016/j.ejheart.2008.10.002. Epub 2008 Nov 12.
9
Clinical trials update from the European Society of Cardiology meeting 2005: CARE-HF extension study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE.2005年欧洲心脏病学会会议临床试验最新进展:CARE-HF扩展研究、ESSENTIAL、CIBIS-III、皮下植入式心律转复除颤器(S-ICD)、ISSUE-2、STRIDE-2、SOFA、IMAGINE、急性心肌梗死院前干预(PREAMI)、西罗莫司洗脱支架评估(SIRIUS-II)及心房颤动导管消融与抗心律失常药物治疗比较研究(ACTIVE)
Eur J Heart Fail. 2005 Oct;7(6):1070-5. doi: 10.1016/j.ejheart.2005.09.006.
10
Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure.阿托伐他汀治疗可能降低晚期慢性心力衰竭患者心源性猝死的发生率。
J Card Fail. 2008 Mar;14(2):140-4. doi: 10.1016/j.cardfail.2007.10.013.

引用本文的文献

1
[Is resynchronization therapy necessary when optimizing right ventricular stimulation?].[优化右心室起搏时是否需要再同步治疗?]
Herzschrittmacherther Elektrophysiol. 2008 Dec;19 Suppl 1:25-37. doi: 10.1007/s00399-008-0604-2.
2
Potential uses of computed tomography for management of heart failure patients with dyssynchrony.计算机断层扫描在心力衰竭合并不同步患者管理中的潜在应用。
Crit Pathw Cardiol. 2008 Sep;7(3):185-90. doi: 10.1097/HPC.0b013e318178eaa5.
3
Insights into myocardial mechanics in normal and pathologic states using newer echocardiographic techniques.
使用更新的超声心动图技术洞察正常和病理状态下的心肌力学。
Curr Heart Fail Rep. 2008 Sep;5(3):143-50. doi: 10.1007/s11897-008-0023-z.
4
3D and 4D echo--applications in EP laboratory procedures.
J Interv Card Electrophysiol. 2008 Aug;22(2):139-44. doi: 10.1007/s10840-008-9248-8. Epub 2008 Apr 18.